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Histologically cirrhosis, a chronic liver disease is characterized by fibrosis and the 
alteration of normal liver architecture into abnormal nodules. In the west, it is the 
leading cause of mortality, particularly affecting the productive age population. In 
our country, an estimated 188,575 cirrhosis related death in 2010
[1] 
which is 18.3 
% of the universal burden of the disease. And the deaths due to cirrhosis increased 
globally from 2005 to 2015, whereas age-standardized cirrhosis mortality rates 
fell during the same period 
[2]
. The economic burden, the disease poses on the 
family of the patient and the patient’s loss of productive life has been overseen 
largely. The complications of cirrhosis are protean including portal hypertension, 
ascites, hepatorenal syndrome, hepatic encephalopathy, portal vein thrombosis, 
hepatocellular carcinoma and eventually death. Besides the complications that are 
disease driven, certain complications are worsened by the therapies instituted for 
the management of cirrhosis, of which beta blockers which have been used for 
managing portal hypertension since the 1980s when Lebrec 
[3]
 et al first 
demontsrated the usefulness of non selective beta blockers in a randomized 
controlled trial involving 74 patients with variceal bleeding, has recently drawn 
the interest of researchers and hepatologists worldwide, when concerns of its 
safety in advanced cirrhosis was raised by Serste
[4]
. 
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Cirrhosis is a final pathway for a wide variety of liver diseases. The rate at which 
the disease worsens from a state of chronic liver disease to cirrhosis varies 
according to the etiology. It could be weeks in complete biliary obstruction to 
decades in case of chronic viral hepatitis C. Whatever maybe the cause, the 
hepatic insult activates profibrogenic mechanisms which leads to progressive 
accumulation of fibrillar extracellular matrix 
[25,26,27]
. The eventual fibrosis leads 
to rise in intrahepatic resistance, which leads to increase in portal and hepatic 
arterial blood flow thereby resulting in portal hypertension.  
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION: 
The hepatic venous pressure gradient (HVPG) of a value greater than 5 mm of 
Hg, defines portal hypertension and is perhaps the most reliable prognostic 
indicator of the formation of varcies and ascites 
[30]
. Hepatic architectural 
distortion leads to increased intrahepatic vascular resistance. Also contributing to 
these are, endothelial dysfunction, intrahepatic vasoconstriction and intrahepatic 
vascular shunts between the afferent and efferent vessels of the organ
[28, 29]
. (Fig 
1)The splanchnic vessels dilate in response to a relatively underperfused liver or 
extrahepatic excess of NO, with sGC-PKG signalling and smooth muscle cell 
relaxation 
[32]
. This leads to increased portal blood flow, which maintains portal 
hypertension. These hemodynamic changes lead to the hyper dynamic circulation, 
which manifests as high cardiac output with low systematic vascular resistance 
and arterial hypotension 
[31]
. The splanchnic vasodialtaion and the imbalance 
between vasoconstrictors and vasodilators are amenable to drug therapy. 
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Figure 1: Pathological mechnanisms involved in  portal hypertension
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PHARMACOLOGICAL ACTION OF BETA BLOCKERS 
Non -selective beta-blockers (NSBB) exert their effects in two main ways to 
reduce the portal pressure. (Fig2).  
1. Firstly, there is beta 1 receptor blockade, which results in reduced cardiac 
output and splanchnic blood flow 
[22]
.  
2. Secondly, beta 2 receptor blockade results in splanchnic vasoconstriction 
caused by unopposed effect of alpha 1 receptors 
[23]
.  
 
Figure 2: Mechanism of action of non selective beta blockers 
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Strikingly the effects of beta 2 blockade occur only after chronic use 
[34]
. The 
response to propranolol therapy as measured by HVPG is variable, with some 
studies reporting to 31 %. (Table 1). Of note, one - third of patients do not have a 
hemodynamic response to propranolol, inspite of studying blood flow patterns in 
azygous system, pointing that all patients may have a reduction in portocollateral 
flow 
[35]
. In an observational study 
[36]
, there was significant difference between 
the acute and chronic effect on HVPG. In those who had poor chronic response, 
they demonstrated increased resistance to portal blood flow. Patients with 
hypertension exhibit a similar response to propranolol as those who are 
normotensive, with a reduction in mean arterial pressure only seen in hypertensive 
patients 
[37]
. Therefore, NSBB are a good choice in hypertensive patients with 
cirrhosis. Nadolol has a longer half-life than propranolol as a result of low lipid 
solubility and hepatic metabolism 
[38]
. This permits once-daily dosage. 
Hemodynamic effects mirror those of propranolol, although effects on mean 
arterial pressure may not be so pronounced 
[33]
. 
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BETA-BLOCKERS USED IN PORTAL HYPERTENSION AND THE PRINCIPLE HEMODYNAMIC 
EFFECTS IN CLINICAL STUDIES 
 
Table 1: Effects of hemodynamic parameters  
N/A, data unavailable; NS, not significant compared to baseline. 
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The most commonly followed algorithms are the AASLD and the BAVENO VI 
guidelines for management of portal hypertension and varices. According to the 
latest AASLD guidelines in 2016 for portal hypertension, those who have 
compensated cirrhosis with mild portal hypertension / clinically significant portal 
hypertension without any gastroesophageal varices, beta blockers are not 
recommended as they are ineffective at this stage and treatment of the underlying 
disease alone is sufficient. In patients who have gastroesophageal varices and or 
bled previously, either primary prophylaxis with EVL or NSBB or secondary 
prophylaxis with the same is recommended depending on the size of the varices. 
In our department, we follow the EASL guidelines for starting the patient on beta 
blocker therapy which is as follows.(Fig 3) 
 
 
 Figure 3: EASL Algorithm for management of Esophageal varices. 
17 
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NON- NSBB MECHANISMS 
Non selective beta blockers may also help in areas other than just reduction of 
portal pressure, like in ascites, hepatorenal syndrome, Hepatic encephalopathy 
and spontaneous bacterial peritonitis. In a promising research work  by Abraldes 
et al it was reported that non selective beta blockers had a positive role in 
preventing ascites, Spontaneous bacterial peritonitis and hepatic encephalopathy 
[39]
.(Table 2) 
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Table : 2 Factors Independently Associated with the Analyzed End Points
[39]
 
 
Analyzed with Cox proportional hazards model. The value of relative hazard 
indicates the relative risk or the strength of association of each variable adjusted 
by the other significant variables. Values above 1 indicate increased risk of 
reaching the end point. Values lower than 1 indicates protective effect. 
Abbreviation: RH, relative hazard. 
Similarly in another study by  Hernandez-Gea et al, showed that patients who had 
compensated cirrhosis and bigger varices, a reduction in the hepatic venous portal 
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gradient more than ten percent was enough to decrease the risk of developing 
ascites and other complications such as refractory ascites and HRS 
[40]
.  
These studies and their findings suggest that beta blockers may benefit cirrhotic 
patients in non portal ways, reducing the risk of ascites, refractory ascites, 
spontaneous bacterial peritonitis hepatic encephalopathy and hepatorenal 
syndrome. In the recent times, much interest has been focused on infections in 
cirrhotics 
[41-43]
. Infections in patients with liver disease pose a severe and 
frequent burden on the health care system as well as the patient’s economy. In 
about, 40 % of patients admitted with cirrhosis in hospitals have infectious 
etiology which in turn leads to prolonged periods of hospitalization and also they 
carry an increased risk for death, around 15 %.
[44,45]
. Not only bacterial infections 
directly contribute to morbidity and mortality, it has also been found in a few 
studies, that they cause increased upper gastrointestinal bleeding 
[46,47]
, difficulty 
in managing variceal bleeders with failures [48] and increased early variceal re -
bleeding rates.
[49]
. Also importantly the occurrence of bacterial infections serves 
as an important time point in the natural course of cirrhosis where the mortality is 
thiry percent at  one month and doubles at one year. 
[50]
. 
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BACTERIAL TRANSLOCATION  
In patients with cirrhosis, quite a significant number of infections is believed to 
because of bacterial translocation (BT), defined as the migration of 
microorganisms or microbial products from the intestinal lumen to the mesenteric 
lymph nodes or other extra-intestinal sites 
[51,52 ]
 (Fig 4). 
 
Figure 4: Compartments and key players involved in mediating pathological BT and the 
associated host response 
[53]
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Three different routes of bacterial translocation can be separated:  
(1) Direct sampling of luminal bacteria (l products) by dendritic cells via 
processes between epithelial cells, not affecting tight junction function 
(2) injured/inflamed epithelium with dysfunctional epithelial barrier and  
(3) M-cells overlying Peyer Patches as specialized cells providing access 
of microbial products to antigen-presenting cells.  
As cirrhosis worsens, there is a parallel increase in the sympathetic activity as 
well. The sympathetic fibers converge on blood vessels, gut associated lymphatic 
tissue and the gut mucosa. There is increased availability of norepinephrine which 
slows the bowel motility, alters the mucosal barrier and blocks chemotaxis and 
phagocytosis. 
[54]
. 
Adding to the above, the raised portal pressure increases intestinal membreane 
permeability by reducing the velocity of blood flow in the mucosal membrane.. 
This leads to phlebectasia and congestion of sub-mucous capillaries and veins 
[55]
. 
So when the total splanchnic blood flow increases due to vasodilatation 
[56]
, an 
erratic distribution in the microcirculation occurs resulting in a decrease in the 
effective mucosal blood flow causing hyperemia, edema, ischemia, and 
potentially erosions 
[55]
. 
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ROLE OF NON SELECTIVE BETA BLOCKERS IN BACTERIAL 
TRANSLOCATION  
Non selective beta blockers play a role in preventing bacterail transllocation. This 
occurs by its nature to reduce the portal pressure and reduce the intestinal 
permeability , thereby decreasing gut mucosal congestion and edema. A seen 
ealier, there is increased gut permeability that leads to endotoxemia. This is 
tackled by beta blockers. 
In experimental animal models with portal hypertension, propranolol has been 
shown to increase bowel transit. Also it decreased the small intestinal bacterial 
overgrowth and its migration into the systemic circulation and thereby preventing 
the development of Spontaneous Bacterial Peritonitis 
[57]
. 
But the same results are not directly available from human studies. Currently the 
only data that is available are post-hoc analyses that have been done on beta 
blockers in relation to development of spontaneous bacterial peritonitis. 
[59, 60, 61]
. 
So the evidence is all coming as derived interpretation, that patients taking non 
selective beta blockers may have a diminished incidence of spontaeous bacterial 
peritonitis. Cholongitas and his colleagues also confirmed the same concepts  in a 
recent meta-analysis . 
[58]
. 
Intestinal permeability can be assessed by ucorse - lactulose mannitol test. 
Bacterial translocation can be assessed by measuring the levels of 
lipopolysaccharide-binding protein, interleukin-6 and malondialdehyde. Reiberger 
et al in a recent study 
[62],
.had researched on the effects of propranolol on 
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intestinal permeability and bacterial translocation. In this study, they had arrived 
at the conclusion that NSBB are able to ameliorate intestinal permeability and 
Bacterial Translocation in cirrhotic patients 
[62]
. Of particular importance, this 
preventive effect seemed to be independent of their hemodynamic effect on portal 
pressure, reinforcing the hypothesis that non selective beta blockers also serve by 
non-hemodynamic mechanisms. Even further, this concept is augmented by the 
fact that patients, even when patients do not have a good hemodynamic response 
to beta blockers , still they had a reduced risk of bleeding which seems to have no 
clear explanation.
[63]
. In the study by Turnes et al, it was shown that when the 
hepatic venous pressure gradient fell by eleven percent , which is suboptimal 
hemodynamic response , still the patients had a reduced incidence of spontaneous 
bacterial peritonitis. 
[59]
. So it is very much possible that there is much more to 
non selective beta blockers benefits in cirrhotics, than just mere reduction in the 
portal pressure. 
NON SELECTIVE BETA BLOCKERS IN REFRACTORY ASCITES 
The effects of non elective beta blockers on refractory ascites are still under 
debate. While NSBB reduce cardiac output and splanchnic blood flow, it may be 
harmful in decompensated cirrhotics especially with refractory ascites. There 
exists already a cardiac impairment in advanced cirrhosis, the cirrhotic 
cardiomyopathy which consists of stress induced systolic incompetence, diastolic 
dysfunction, and electrophysiological abnormalities 
[69,70,71]
. The underlying 
mechanism in cirrhotic cardiomyopathy involves abnormal signaling in the beta 
adrenergic pathway ,increased sodium , plasma expansion and the presence of 
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substrates that have a negative ionotropic effect. All these lead to cardiomyocyte 
hypertrophy which may possibly have an effect on the channel defects 
[72,73]
. Most 
of the time, the cardiomyopathy part is well tolerated and is not manifested 
clinically. But when there is a situation where the peripheral arterial 
vasodilatation becomes worse , as in the placement of a TIPS or a large volume 
paracentesis or spontaneous bacterial peritonitis where the endotoxins can cause 
vasodilatation , the hearts  systolic incompetence becomes clinically 
evident
[74,75,76]
. Theoretically if one uses a non selective beta blocker in this 
situation, it would add more damage. Lebrec et al, who was the first to 
demonstrate usefulness of beta blockers for portal hypertension also researched on  
the hemodynamic effects and the impact on survival of non selective beta 
blockers use in patients with refractory ascites 
[3, 4]
. The study had 151 patients 
enrolled , half of whom had large esophageal varices that required treatment with 
non selective beta blockers , whereas only 4 patients did take NSBB without any 
varices. The reasons for the staring of beta blockers in both of the situations were 
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not clearly mentioned. 
 
Figure 5 Serste et al, Hepatology.Survival analysis. 
 
It was reported to be a median survival of five months in patients taking beta 
blockers while those not taking beta blockers had a median survival of 20 
months.(Fig 5)The authors opined that the use of NSBB in decompensated 
cirrhotic patients with refractory ascites might be dangerous. The results of these 
studies though initially created alarm, was later criticized because of its 
observational design and not a randomized controlled design. Also the gold 
standard of measuring portal hypertension, HVPG measurement was done only in 
a small number of the patients.. The difference in the hepatic venous pressure 
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gradient was expected, because of the prevalence of varices. Another criticism 
arose regarding the cause of deaths in which 25 were unknown. These were in 
contrast to previous findings in which NSBB had a protective role against 
infections. Also the mortality rates were higher when compared to previous 
studies 
[77,78]
.  
The same group, to evaluate their hypothesis further, did a cross-over study to 
look at the impact of non selective beta blockers on the development of 
paracentesis induced circulatory dysfunction (PICD) 
[79]
. PICD is a syndrome of 
circuatory disturbance typically occurring after large-volume paracentesis which 
is characterized by systemic vasodilatation and decrease in effective arterial blood 
flow. It is associated with reduced survival. They took 10 cirrhotic patients with 
refractory ascites taking non selective beta blockers. All underwent large volume 
paracentesis and beta blocker therapy was terminated after varices were 
eradicated by endoscopic variceal ligation. Clinical follow up and repeated 
paracentesis were done. 
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Figure 6: Serste et al , Hepatology. Incidence of Paracentesis induced circulatory 
dysfunction. 
Incidence of PICD remarkably reduced from eighty  percent to ten percent when 
the non selective beta blockers were stopped. This suggested that beta blockers 
negatively affect the hemodynamic status which is already compromised in 
patients with advanced cirrhosis(fig 6). However, these results cannot be 
extrapolated to the clinics, considering the small sample size. Much more studies 
are needed, before one can withdraw beta blocker therapy in a patient with End 
stage liver disease (ESLD). 
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BETA BLOCKER WINDOW HYPOTHESIS 
In the work by Lebrec’s group , arose the concept of the β-blockers ‘therapeutic 
window’ hypothesis in cirrhosis 
[80]
. This hypothesized that, non selective beta 
blockers have no effects in early cirrhosis because the so called clinically 
significant portal hypertension (HVPG≥10 mm Hg) has not yet been reached and 
there are no medium or large varices and sympathetic nervous system (SNS) 
activity is also remaining normal 
[81]
. As the disease worsens, the portal pressure 
worsens, splanchnic hyperemaia ensues , sympathetic activity increases and 
bacterial translocation increases. At this point, the therapeutic window opens and 
current guidelines recommend prophylaxis with NSBBs. Further in the disease 
course, the peripheral arterial dilatation becomes prominet. Blood pressure (BP) 
and organ perfusion integrity become critically dependent on cardiac output. So at 
this stage, knocking out the cardiac output by beta blockers would lessen the 
survival and is unfavourable 
[82,83,84]
. Even more, in refractory ascites there is a 
decreased sensitivity to the β-adrenergic blockade in favour of the α-adrenergic 
blockade secondary to raised levels of splanchnic proinflammatory cytokines, 
with a resulatnt reduction in NSBBs’ beneficial effects 
[85]
.(Fig 7) In this stage, 
using non selective beta blockers could be harmful. The therapeutic window 
closes theoretically. But still there have been many studies refusing this theory 
and the exact role of NSBBs needs further clarification. 
 
 
30 
 
 
 
 
Figure 7: The window hypothesis 
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HEPATORENAL SYNDROME AND AKI 
Hepatorenal syndrome (HRS) is a distinct cause of renal impairment of functional 
origin that occurs in patients with liver cirrhosis (Fig 8). But patients with 
cirrhosis can also develop Acute Kidney Injury (AKI) besides Hepatorenal 
Syndrome due to other causes, such as prerenal azotemia, intrinsic acute kidney 
injury, sepsis, nephrotoxic drugs, and parenchymal nephropathy 
[86,87]
. AKI must 
be differentiated from HRS because the treatments differ. Here come in the role of 
biomarkers that help categorize the type of renal failure and predict or stage renal 
dysfunction. Lot of studies have reported the potential of NGAL as an early 
marker in the differential diagnosis of AKI in cirrhosis 
[88]
. Another molecule, 
CysC a non-glycosylated protein is thought to be a more reliable marker of 
glomerular filtration rate (GFR) as it is less influenced by age, sex, muscle mass, 
or serum bilirubin levels than serum creatinine. However, results in patients with 
cirrhosis are limited and nonconclusive. 
In a study by  Ruiz-del-Arbol et al (92), he reported that patients who had 
spontaneous bacterial peritonitis , developed  renal impairment in association with  
decreased cardiac output and mean arterial pressure which makes plausible why 
NSBB therapy would be dangerous for survival of patients with fairly advanced 
cirrhosis. Similar studies have  induced authors to reconsider peripheral 
vasodilation hypothesis, adding to the widely accepted cascade of a final stage 
characterized by a hyperdynamic circulation that comes down as a consequence 
of a relative failure of cardiac output(93).So, the negative inotropic and 
hypotensive effects of NSBBs could be deleterious for patients with advanced 
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cirrhosis and refractory ascites and/or HRS. But surprisingly, many other research 
have continued to prescribe NSBBs to patients with advanced cirrhosis proposing 
that the methodological quality of the available research materials are not enough 
to making the results reliable (94). 
Therefore, the use of NSBBs in patients with advanced cirrhosis has become an 
issue of debate between those who are concerned upon the safety of NSBBs given 
to patients with severe cirrhosis and those who critics the quality of the methods 
used to generate the evidence of negative effects of NSBBs in cirrhosis.  
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Figure 8: Pathophysiology of Hepatorenal syndrome. 
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HEPATIC ENCEPHALOPATHY  
Hepatic encephalopathy (HE) encompasses all the neuropsychiatric abnormalities 
that develop in the setting of portal hypertension. Overt HE develops in 30–45 % 
of patients with cirrhosis 
[32]
. Subclinical HE is more subtle and characterized by 
psychomotor slowing, visuoconstructive disabilities, and attention deficits. It is 
present in up to 80 % of cirrhotics 
[90]
. Hepatic Encephalopathy is precipitated by 
neurotoxins normally cleared by the liver, but that are shunted around the liver in 
the presence of portal hypertension-induced portosystemic collaterals, allowing 
them to influence the central nervous system. (fig 10). Patients hospitalized with 
HE experience mortality rates of 42 % at 1 year and 23 % at 3 years 
[91]
. 
Commonly used test to detect at bed side which is easily available is the 
psychometric tests (Fig 9). 
 
Figure 9: Psychometric Encephalopathy Score tests. 
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Figure 10:  THE LANCET - Pathophysiology of Hepatic Encephalopathy  
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AIMS AND METHODOLOGY 
 
 
 
 
 
 
 
 
 
37 
 
AIM OF THE STUDY 
Aimed to analyze the impact of beta blockers on the following complications in 
cirrhosis:  
1. Spontaneous bacterial peritonitis (SBP) 
2. Refractory ascites 
3. Hepatorenal syndrome (HRS) and  
4. Hepatic encephalopathy (HE)  
in patients who did or did not take non-selective beta blockers and thereby to test 
the null hypothesis that beta blockers cause worsening of the above mentioned 
complications. 
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MATERIALS AND METHODS 
Study Design  : Single centre, case control retrospective study. 
Study centre : Department Of Digestive Health and Diseases, Kilpauk 
Medical College and Hospital, Kilpauk Medical College, 
Chennai. 
Period of Study  : 2 years ( January 2015 to January 2017) 
Study population  : In Patients and Outpatients having cirrhosis and portal 
hypertension who were registered with the Department of Digestive Health and 
Disease between the period January 2009 to January 2016.  
Inclusion criteria  : Patients having cirrhosis with portal hypertension. 
Exclusion criteria : Patients who had significant cardiovascular disease, 
extrahepatic malignancy, intrinsic renal disease and those not willing to provide 
consent were excluded from this study.  
Financial Assistance : Nil 
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METHODOLOGY 
Patients were identified from a prospectively collected data base. The following 
parameters were recorded at the time of enrollment to study: age, sex, duration of 
disease, number of hospital admissions for cirrhosis related illnesses, history of 
diabetes, history of upper gastrointestinal bleeding, presence of cirrhotic 
cardiomyopathy, portal vein thrombosis. Biochemical parameters such as 
complete blood count, renal function test, and liver function test were done. The 
MELD
[5]
 and CTP
[6,7]
 score were calculated based on the bilirubin, creatinine, 
PT/INR, albumin, presence of ascites and Hepatic Encephalopathy. 
Esophagogastroduodenoscopy was done in all patients and esophageal 
varices
[9,10]
, gastric varices
[8]
 and portal hypertensive gastropathy
[11]
 were 
identified and graded accordingly. The occurrence of spontaneous bacterial 
peritonitis, refractory ascites, hepatorenal syndrome and hepatic encephalopathy 
were also noted.  
The diagnosis of spontaneous bacterial peritonitis and encephalopathy were based 
on clinical, biochemical and microbiologic data as interpreted by the treating 
physician.  
Refractory ascites and hepatorenal syndrome were diagnosed by the definitions 
proposed by the International Ascites Club. 
The International Ascites Club criteria  for Hepatorenal Syndrome  is as follows : 
1. Presence of cirrhosis and ascites 
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2. Serum creatinine >1.5 mg/dL (or 133 micromoles/L) 
3. No improvement of serum creatinine (decrease equal to or less than 1.5 mg/dL) 
after at least 48 hours of diuretic withdrawal and volume expansion with albumin 
(recommended dose: 1 g/kg b.w. per day up to a maximum of 100 grams of 
albumin/day) 
4. Absence of shock 
5. No current or recent treatment with nephrotoxic drugs 
6. Absence of parenchymal kidney disease as indicated by proteinuria >500 
mg/day, microhematuria (>50 RBCs/high power field, and/or abnormal renal 
ultrasound scanning. 
Refractory ascites was defined as that ascites which recurred early , cannot be 
mobilized  and not prevented by medical therapy. It is of two types :  
1. Diuretic intractable , which is the condition in which diuretics dosage cannot 
be increased due to diuretics induced complications.  
2. Diuretic resistant , which is the state where maximum dose of diuretics has 
been used , but still fails to mobilize ascetic fluid.s 
Echocardiogram and electrocardiogram were also done in all patients to look for 
cirrhotic cardiomyopathy. Portal Venous Doppler (PVD) was also done to look 
for portal venous thrombosis. 
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                                                              PROFORMA 
Name :                                       Age:                                 Sex:                                    DDHD no: 
Duration of illness:                          Etiology of cirrhosis:                  No of hospital admissions: 
Comorbid illness: 
Medications: 
Beta blockers : yes/ no 
MELD  score:                       CTP Score:                           DF: 
Previous history of GI bleed and therapy : 
Presence of HRS: 
Presence of Hepatic Encephalopathy: 
Presence of Refractory Ascites: 
Presence of Spontaneous bacterial peritonitis: 
INVESTIGATIONS 
Bili total  Hb%  HBsAg  USG abdomen 
Bili direct  TC  Anti-HCV  
SGOT  DC  HIV  
SGPT  Platelets  PT/INR  
SAP  Urine alb  MHE  Portal Doppler 
Tot prot  RBS  ECG  
S.alb  Bl.urea  Echo  
S.glob  S.creat    
 
Esophago gastroduodenoscopy: 
Presence of varices:                                                               Grading :            
Ascitic fluid analysis: 
TC                         DC                          Protein                       Albumin                 SAAG                Cytology 
Culture and sensitivity                 
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STATISTICS 
Statistical analysis was done using SPSS software version 2.0. All quantitative 
data were expressed in Mean ± SE. Chi square analysis was done to compare the 
frequency of complications in the NSBB and non - NSBB groups. P< 0.05 was 
considered significant.  
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RESULTS 
 
 
 
 
 
 
 
 
 Demographic data: 
A total of 82 patients were included in this study. The mean age of the entire 
cohort was 47.91 years. Predominantly our cohort ha
79.3%) (Fig 11). The overall mean duration of disease was 1.5 years. 
Figure 11: Sex wise distribution
The common etiology for liver cirrhosis was ethanol (n = 61, 74.39%), followed 
by Chronic viral Hepatitis 
steatohepatitis and Hepatitis C. Four patients had both Hepatitis B and significant 
alcohol consumption .  
d male patients (n= 65, 
 
 
B (n = 9, 10.97%) cryptogenic, non alcoholic 
17, 21%
65, 79%
Sex wise distribution 
Female Male
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Figure 12: Etiology of cirrhosis  
Of the 82 patients, 44 patients (53.6 %) were on non selective beta blockers and 38 patients (46.3%) were not on beta 
blockers
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 HOSPITALIZATION: 
The numbers of hospitalizations were
those not taking it (Fig 14). But whether beta blockers directly
related admissions cannot be concluded from this observation, because of several confounding 
factors like the severity of disease, high MELD / CTP , comorbidities, ongoing alcohol use and 
non compliance with drugs.  
 
Figure 14: Cummulative Hospital Admissions
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FREQUENCY OF UPPER GASTROINTESTINAL BLEED  
41.66% of patients (n= 35) had a history of upper gastrointestinal bleeding in the 
past in the form of hemetemesis / melena or both. Predominantly the bleeders 
were from the NSBB group (n= 24, 68.6 %) and the non NSBB patients bled in 
few numbers (n= 11,31.4%) as one would expect, so the p value was significant 
(Fig15/Table 3). 
 
Table 3: Number of bleeders in both groups 
UGI 
BLEED 
BETA BLOCKER 
TOTAL 
P-
VALUE YES NO 
YES 24(54.5%) 11(29.7%) 35(43.2%) 
0.025 
NO 20(45.5%) 26(70.3%) 46(56.8%) 
TOTAL 44 37 81 
 
 
 Figure 15: UGI bleeding in both groups
 
FREQUENCY OF DIABETES AMONG NSBB AND non NSBB
17 patients had diabetes (20.7%) in this 
NSBB group and 6 patients (35.3%) in the non NSBB group had diabetes.
Because diabetes can predispose to infections, this parameter was also included in 
the study. But the p value was 0.341 , when compared against both groups, 
suggesting that diabetes is not contributing to the complications of 
16/Table 4). 
Table 4: Number of Diabetes in both groups
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 PATIENTS 
study group. 11 patients (64.7 %) in the 
cirrhosis (Fig 
 
UGI Bleed No
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NSBB No
NSBB Yes
  
DIABETES 
BETA BLOCKER
YES 
YES 11(26.2%)
NO 31(73.8%)
TOTAL 42 
 
 
Figure 16: Diabetes in complications 
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TOTAL NO 
 6(17.1%) 17(22.1%) 
 29(82.9%) 60(77.9%) 
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FREQUENCY OF CIRRHOTIC CARDIOMYOPATHY AMONG NSBB 
AND non NSBB PATIENTS  
Ten patients (12.2%) had cirrhotic cardiomyopathy. Those on beta blockers, 60 % 
(n=6) developed cirrhotic cardiomyopathy and 40 % (n= 4) of patients not taking 
non selective beta blockers developed cardiomyopathy. There are studies that 
have observed decreased QT intervals in cirrhotic cardiomyopathy while on beta 
blocker therapy (95.) In this study, such protective effect on the cardiac myocyte 
by beta blockers was not observed. (p=0.293) (Fig 17/Table 5). 
 
Table 5: Cirrhotic Cardiomyopathy in both groups 
CIRRHOTIC BETA BLOCKER 
TOTAL 
P-
VALUE CARDIOMYOPATHY YES NO 
YES 6(30%) 4(16.7%) 10(22.7%) 
0.293 
NO 14(70%) 20(83.3%) 34(77.3%) 
TOTAL 20 24 44 
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Figure 17: Frequency of cirrhotic cardiomyopathy 
 
FREQUENCY OF PORTAL VEIN THROMBOSIS AMONG NSBB AND 
non NSBB PATIENTS  
Only two patients (2.4%) in this study group had portal vein thrombosis(PVT). 
And both the patients were not on beta blockers. As  mentioned earlier, few 
papers have suggested that beta blockers can also decrease the incidence of portal 
vein thrombosis. In our study, such a difference was not evident (p=0.167) (Fig 
18/Table 6). 
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 Table 6: Portal vein thrombosis in both groups
PVT 
BETA BLOCKER
YES 
YES - 
NO 21(100%)
TOTAL 21 
 
Figure 18:Frequency of portal vein thrombosis
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TOTAL P-VALUENO 
2(8.7%) 2(4.5%) 
0.167
 21(91.3%) 42(95.5%) 
23 44 
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Figure 19: Severity of portal hypertension among NSBB and non NSBB patients  
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FREQUENCY OF THROMBOCYTOPENIA AMONG NSBB AND non 
NSBB PATIENTS  
The mean platelet count in this study group was overall less (96000 cells /mm
3
) 
than the normal (1.5 to 3.5 lakhs /mm
3
 ), well correlating with the existing 
concept of 'lower the platelet count (<88,000) ,higher the portal pressure. So 
naturally, these patients were on non selective beta blockers (Fig 20/Table 7). 
 
Table 7: Thrombocytopenia across both groups 
Parameter NSBB Non NSBB Overall 
PLATELET (in 
Thousands)
 §
 
88(62.75-
132.25) 
110(61.25-
180.75) 
96(62-
156.75) 
  
N(%) are given in parenthesis; 
¶
Mean ± SD; 
§
Median (IQR) 
 
 Figure 20: Platelet distribution
PATIENTS ON 
SPONTANEOUS BACTERIAL PERITONITIS
34 patients (41.5%) were taking 
(52.9%) were in the NSBB and 16 (47.1%) were in the non 
In our hospital, we use Norfloxacin for 
Peritonitis. The antibiotic prophylaxis did not affect the outcomes , esp 
spontaneous bacterial peritonitis , because the p value was insignificant (p=0.913
(fig 21/Table 8). 
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(Fig 21) 
acterial 
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 Table 8: Antibiotic Prophylaxis in both groups
NORFLOX 
  YES 
YES 18(40.9%)
NO 26(59.1%)
TOTAL 44 
 
Figure 21: Antibiotic prophylaxis in both groups
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BETA BLOCKER TOTAL P-
NO     
 16(42.1%) 34(41.5%) 
0.913
 22(57.9%) 48(58.5%) 
38 82 
Norflox No
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VALUE 
 
 
NSBB Yes
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Table 9: COMPARISON OF NSBB AND non-NSBB PATIENTS  
PARAMETERS  
BETA BLOCKER  
OVERALL (N=82)  
YES (N=44)  NO (N=38)  
AGE (yrs)
¶
  48.41±9.29  47.34±7.32  47.91±8.41  
SEX        
 MALE  33(50.8%)  32(49.2%)  65 
 FEMALE  11(64.7%)  6(35.3%)  17 
DURATION OF ILLNESS (yrs)
§
  2.0 (0.5-3.75)  1.0 (0.48-2.25)  1.5 (0.5-3.0)  
MELD
§
  17(12-18)  16(12.5-18)  17(12-17)  
UGI  24(68.6%)  11(31.4%)  35 
PLATELET(in Thousands)
 §
  88(62.75-132.25)  110(61.25-180.75)  96(62-156.75)  
DIABETES  11(64.7%)  6(35.3%)  17 
CIRRHOTIC 
CARDIOMYOPATHY  
6(60%)  4(40%)  10 
PVT  0(0%)  2(100%)  2 
SBP PROPHYLAXIS  18(52.9%)  16(47.1%)  34 
SBP  15(45.5%)  18(54.5%)  33 
REFRACTORY ASCITES  6(54.5%)  5(45.5%)  11 
HRS  2(25%)  6(75%)  8 
HE  7(38.9%)  11(61.1%)  18 
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FREQUENCY OF SPONTANEOUS BACTERIAL PERITONITIS  
33 patients (40.2%) were observed to have spontaneous bacterial peritonitis. 15 
patients (45.5%) from the NSBB and 18 patients (54.5%) from the non NSBB 
group had developed spontaneous bacterial peritonitis at least once in their course 
of the illness (Table 10/Fig 22). 
 
Table 10: Frequency of SBP in both groupss 
SBP NSBB Non NSBB Total 
YES 15(45.5%) 18(54.5%) 33 
NO 29(59.2%) 20(40.8%) 49 
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Figure 22: Frequency of spontaneous bacterial peritonitis  
ASSOCIATION OF BETA BLOCKER THERAPY AND SPONTANEOUS 
BACTERIAL PERITONITIS  
The association between use of beta blockers with spontaneous bacterial 
peritonitis was checked using chi-square analysis. And it is found that use of beta 
blockers is not a risk factor nor a protective one for spontaneous bacterial 
peritonitis(p=0.221) (table 11) 
 
 
15
18
29
20
0 5 10 15 20 25 30 35
BB Yes
BB No
Beta Blocker & SBP
SBP No
SBP Yes
60 
 
 
Table 11: Chi Square analysis for SBP 
  Value df 
Asymp. Sig 
(2-Sided) 
Exact Sig. 
(2-Sided) 
Exact Sig. 
(1- Sided) 
Pearson Chi-Square 1.495
a
 1 0.221 0.263 0.159 
Continuity Correction
b
 0.994 1 0.319     
Likelihood Ratio 1.496 1 0.221 0.263 0.159 
Fisher's Exact Test       0.263 0.159 
Linear - by - Linear 
Association 
1.477
c
 1 0.224 0.263 0.159 
N of Valid Cases 82         
 
FREQUENCY OF REFRACTORY ASCITES 
11 patients (13.4%) had refractory ascites. This comprised 6 patients (54.5%) 
from those on non selective beta blockers and 5 patients (45.5%) from the non -
NSBB group (Table 12). 
Table 12: Frequency of Refractory Ascites 
REFRACTORY 
ASCITES NSBB Non NSBB Total 
YES 6(54.5%) 5(45.5%) 11 
NO 38(53.5%) 33(46.5%) 71 
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Figure 23: Frequency of Refractory Ascites 
ASSOCIATION OF BETA BLOCKER THERAPY AND REFRACTORY 
ASCITES  
Analysis of beta blocker and refractory ascites for aascoiation by Pearson Chi 
syuared analysis showed a asymptote significnce of 0.949 , which implies that 
there is no association between beta blockers and refractory ascites.  
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Table 13: Chi-square analysis for Refractory Ascites 
  Value df 
Asymp. 
Sig (2-
Sided) 
Exact 
Sig. (2-
Sided) 
Exact Sig.(1- 
Sided) 
Pearson Chi-Square 0.004
a
 1 0.949 1.000 0.605 
Continuity Correction
b
 0 1 1.000     
Likelihood Ratio 0.004 1 0.949 1.000 0.605 
Fisher's Exact Test       1.000 0.605 
Linear - by - Linear 
Association 
0.004
c
 1 0.950 1.000 0.605 
N of Valid Cases 82         
 
FREQUENCY OF HEPATORENAL SYNDROME  
Of this group only 8 patients (9.8%) had hepatorenal syndrome which was 2 
(25%) from the NSBB and 6 (75%) from the non NSBB group (Table 14/Fig 24). 
Table 14: Frequency of HRS 
HRS NSBB 
Non 
NSBB Total  
YES 2(25%) 6(75%) 8 
NO 42(56.8%) 32(43.2%) 74 
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Figure 24: Frequency of HRS 
 
ASSOCIATION OF BETA BLOCKER THERAPY AND HEPATO RENAL 
SYNDROME  
In the Chi square analysis for hepatorenal syndrome and beta blocker use, the 
asymptote significance was 0.087. And the Fisher's Exact test was 0.136 ( 2 -
sided). Thus, beta blockers have no role in the occurence of hepatorenal 
syndrome. 
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Table 15: Chi-square analysis for HRS 
  Value df 
Asymp. Sig 
(2-Sided) 
Exact Sig. 
(2-Sided) 
Exact Sig. 
(1- Sided) 
Pearson Chi-Square 2.928
a
 1 0.087 0.136 0.090 
Continuity Correction
b
 1.79 1 0.181     
Likelihood Ratio 3.009 1 0.083 0.136 0.605 
Fisher's Exact Test       0.136 0.605 
Linear - by - Linear 
Association 
2.892
c
 1 0.089 0.136 0.605 
N of Valid Cases 82         
 
 FREQUENCY OF HEPATIC ENCEPHALOPATHY  
A total of 18 patients developed Hepatic encephalopathy at least once in their 
course of illness. Of these, 7 patients (38.9 %) belonged to the NSBB and 11 
patients (61.1%) to the non NSBB group (Table 16/Fig 25). 
Table 16: Frequency of HE 
HE NSBB Non NSBB Total 
YES 7(38.9%) 11(61.1%) 18 
NO 37(57.8%) 27(42.2%) 64 
 
65 
 
 
Figure 25: Frequency of HE 
 
ASSOCIATION OF BETA BLOCKER THERAPY AND HEPATIC 
ENCEPHALOPATHY 
In a chi-square analysis of hepatic encephalopathy against the use of beta blockers 
showed no significant association (asymptomatic significance = 0.155). The Fisher's 
Exact test showed an exact significance (2 sided) of 0.187. Once again, beta blockers 
neither protect from nor precipitate .hepatic encephalopathy . 
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Table 17: Chi-square analysis for HE 
  Value df 
Asymp. 
Sig (2-
Sided) 
Exact 
Sig. (2-
Sided) 
Exact Sig.(1- 
Sided) 
Pearson Chi-Square 2.023
a
 1 0.155 0.187 0.124 
Continuity Correction
b
 1.334 1 0.248     
Likelihood Ratio 2.026 1 0.155 0.187 0.124 
Fisher's Exact Test       0.187 0.124 
Linear - by - Linear 
Association 
1.999
c
 1 0.157 0.187 0.124 
N of Valid Cases 82         
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DISCUSSION 
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In this single centre, retrospective study we analyzed effects of non selective beta 
blocker therapy on the complications of cirrhosis in 82 patients.  
As shown in this Chi - Square analyses, the p values were insignificant when the 
association of beta blockers were tested against hepatic encephalopathy, 
hepatorenal syndrome, spontaneous bacterial peritonitis and refractory ascites. 
As an added point of interest , we also looked at beta blockers  if they could 
protect against cirrhotic cardiomyopathy being protective against cirrhotic 
cardiomyopathy as it would work against any cardiomypathy and cardiac failure 
(95). On the contrary, we did not find any such protective effect against the 
cardiac myocyte.  
Also, beta blockers have been accused to be detrimental in the setting of End 
stage liver disease and especially those with Spontaneous Bacterial peritonitis 
where the predisposition to Hepatorenal syndrome is high. In this study, beta 
blockers use in those with advanced cirrhosis , as evident by their MELD did not 
affect the outcome of complications. 
Again as an added interest, we wanted to see if beta blockers could also lead to  
portal vein  thrombosis (96), Hypothetically, non selective beta blockers reduce 
the portal vein inflow and portal pressure and thereby lead to thrombosis in the 
lumen. But in this study, we did not any increased occurrence of portal vein 
thrombosis in patients taking beta blockers.  
The dose of beta blockers used in our study was less when compared to the 
western data. All our patients had only received propranolol . The maximum dose 
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of propranolol used in this study was 120 mg /day, because of the unwanted side 
effects like bradycardia and hypotension. Still most patients tolerated the titration 
of beta blockers against their heart rates. 
We also looked if diabetes , a predisposing factor for infection be a confounding 
factor . But diabetes incidence was also similar in both subgroups.  
The early concerns of the safety of beta blockers stems from the Serste 
[4]
 et al 
who analyzed the impact of administering non selective beta blockers on the long-
term survival in cirrhotics, with refractory ascites. The predominant cause of 
cirrhosis in both the NSBB and non NSBB group was ethanol, as in our study. 
Among the complications of our study, the frequency of hepatic encephalopathy 
and renal dysfunction were in line with the Serste study (p value for Hepatic 
encepahalopathy = 0.38, p value for renal dysfunction = 0.07), despite the Serste 
study having a higher mean MELD than our study patients. 
Serste in his observational study had observed that in refractory ascites, mortality 
increases at one year by four times when beta blockers are used. Whether beta 
blockers contribute to refractoriness of ascites, in the first place remains 
unknown. In this study we found no association between beta blockers and 
refractory ascites. 
On the contrary,Mandorfer et al 
[12]
 found an association between beta blockers 
and renal dysfunction in cirrhotics. But all these patients already had Spontaneous 
bacterial peritonitis which by itself can precipitate Hepatorenal syndrome 
irrespective of beta blockers usage.  
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Figure 26: Transplant free survival in NSBB and non NSBB, Mandorfer et al 
The same group also identified that beta blocker therapy did not affect the 
occurrence of Spontaneous bacterial peritonitis which is in line with our data.But 
patients who were not on beta blockers and did not have Spontaneous Bacterial 
peritonitis had a good transplant free survival compared to those who did not take 
beta blockers. Also these patients had fewer non elective hospitalizations (Fig 26). 
In this study, we did not have transplant patients which was a drawback and we 
could not anlayse if beta blockers impacted the transplant free survival chances. 
In a study by Kimer et al 
[13]
, in 2014, they had retrospectively collected 61 
patients with refractory ascites and looked for the complications of Hepato renal 
syndrome, Spontaneous Bacterial peritonitis, Hepatic encephalopathy, 
hospitalizations, bleeding frequencies and death in NSBB and non NSBB groups. 
Except for death, which we did not include in our study, the rest of the parameters 
were similar to the Kimer's study.  
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Table 18: Development of complications., Kimer et al. 
A similar evidence comes from  Poynard et al 
[14]
 who published a meta analysis 
in 1991 NEJM which included four randomized controlled studies that compared 
beta blockers and placebo in regards to bleeding, fatal bleeding and death. It was 
also observed in the study that ascites and beta blocker therapy may influence 
survival. Yet, the two factors were not linked in statistical analysis. Among these 
RCTs included, one RCT by Pascal et al  
[15]
), where patients were stratified 
according to their Child Pugh score, the effect of non selective beta blocker on 
death rate was independent of severity of liver disease; on the corollary, beta 
blocker therapy did not affect the morbidity of cirrhotics even if they were Child 
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C. In our study group also we had Child C patient who did well with beta 
blockers. 
In a Letters to the Editors to Hepatology 2011, Galbois et al wrote on 
retrospectively analyzing 68 patients admitted to ICU with cirrhosis and sepsis. 
They observed no difference in mortality between NSBB and non-NSBB-treated 
patients. Though we have not included ICU patients, NSBB were already having 
no impact in our patients with our ESLD patients.  
In a similar kind of Letters to Editors to the same journal, in 2014, Robbins et al,
 
[17]
 after analyzing one hundred and fourteen patients retrospectively who were 
undergoing regular abdominal paracentesis, they reported that there was no 
significant difference in survival between those taking NSBB versus those who 
did not. This is again in line with our study. 
In another study comparing the effects of primary prophylaxis with beta blocker 
either alone or combined with endoscopic sclerotherapy vs no treatment, the 
PROVA study 
[18]
, a higher mortality was seen in the combined group. But the 
groups with beta blocker alone and no treatment had no significantly different 
mortality. 
Aday et al,
[19] 
did a retrospective study with a striking number of 2419 patients, 
with cirrhosis and portal hypertension. Patients were grouped as to having ascites 
only, varices only and having both. The outcome of interest was all cause -in 
hospital- mortality. It was concluded patients on beta blockers were less likely to 
die than those not on beta blockers. And this significant survival benefit was 
spread across all grades of ascites, even the most severe ones. This is in great 
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contradiction to the Serste study which was a case only study of 151 patients, 
when compared to this large numbered study. 
Aligned with the previous study, Leithead et al, in Gut 2015, did a single centre 
observational retrospective study, taking patients with ascites who were listed for 
liver transplant and that beta blockers do not cause harm. Instead they are 
associated with decreased transplant-free mortality and reduced death during the 
waitlisted period. This again is an opposite conclusion of Serste study and a few 
others who did not support the use of beta blockers in advanced liver disease. 
In a study by Qi X-S et al, 
[21] 
in World journal of gastroenterology 2014, it was 
suggested that beta blockers can lead to formation of thrombus in the portal vein. 
This was hypothesized due to the reduced cardiac output an splanchnic 
vasoconstriction that occurs in beta blocker therapy. These events can reduce 
portal venous blood flow velocity which eventually precipitates portal vein 
thrombosis.  
But subsequently in a recent large longitudinal cohort analysis, 
[22] 
by Nery et al 
Hepatology 2015, they studied 1243 patients who did not have hepatocelluar 
carcinoma concluded that beta blocker therapy did not cause portal vein 
thrombosis. In our study also beta blocker therapy was not protective or a risk for 
portal vein thrombosis. 
In those cirrhotics with End stage Liver Disease, immunological malfunctioning 
like altered phagocytic activity, hypocomplementemia, reduced bactericaidal and 
opsonic activity prevails which may all predispose to bacterial infections 
[58,64]
. 
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In Acute on Chronic Liver Failure, bacterial infections are a common causative 
factor. And non selective beta blockers have been demonstrated to improve  
survival at 1 month and at three months in Acute on chronic liver failure 
[65]
. But 
these data were obtained from a post hoc analysis of the CANONIC cohort. 
As obvious these results have been challenged by other researchers with an NSBB 
group experiencing a increased incidence of renal and cerebral failure despite a 
reduction in sepsis. But the overall in- hospital or 3 month outcomes were 
untouched by non selective beta blockers 
[66]
. 
Also possible is endotoxaemia to occur more frequently in advanced liver disease, 
regardless of variceal status, which can exacerbate hyperdynamic circulation(67). 
As already discussed beta blocker mediated  reduction of intestinal permeability 
and bacterial translocation may be partly independent of portal pressure reduction 
mechanisms.
[62,68]
  
 
Chi - square analyses had shown no significant association between the uses of 
NSBB with any of these variables.  
Beta blockers are said to reduce the incidence of spontaneous bacterial peritonitis 
by altering gut mucosal permeability. In our analyses, we did not find any 
protective effect of beta blockers against spontaneous bacterial peritonitis. 
NSBB has also been found to increase the risk for hepatorenal syndrome, as 
quoted in the recent study by Mandorfer et al in 2014
[6]
. Again in our study 
population, we did not find any significant association between beta blockers use 
and the occurrence of hepatorenal syndrome. 
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Earlier, there were concerns about propranolol raising serum ammonia 
[7,8]
 and 
precipitating hepatic encephalopathy
[9]
 in patients with cirrhosis. In our study, 
which was conducted in resource limited setting, serum ammonia levels could not 
be done. Still, our data and statistical analysis did not demonstrate significant 
association between beta blockers and the occurrence of overt or covert hepatic 
encephalopathy. 
. 
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CONCLUSIONS 
In this study , no significant statistical association was found between the NSBB group versus 
the non NSBB group in terms of the following 4 complications of cirrhois: 
1. Spontaneous Bacterial peritonitis 
2. Refractory Ascites 
3. Hepatorenal syndrome. 
4. Hepatic encephalopathy. 
To conclude, in this study non selective beta blockers are neither protective nor a risk factor for 
spontaneous bacterial peritonitis, refractory ascites, hepatorenal and hepatic encephalopathy.  
And therefore, we suggest that beta blockers can be continued safely in cirrhotics 
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LIMITATIONS 
1. Retrospective study 
2. Small sample size 
3. Serum ammonia not measured in patients with hepatic encephalopathy. 
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PROFORMA 
Name :                                       Age:                                 Sex:                                    DDHD no: 
Duration of illness:                          Etiology of cirrhosis:                  No of hospital admissions: 
Comorbid illness: 
Medications: 
Beta blockers : yes/ no 
MELD  score:                       CTP Score:                           DF: 
Previous history of GI bleed and therapy : 
Presence of HRS: 
Presence of Hepatic Encephalopathy: 
Presence of Refractory Ascites: 
Presence of Spontaneous bacterial peritonitis: 
INVESTIGATIONS 
Bili total  Hb%  HBsAg  USG abdomen 
Bili direct  TC  Anti-HCV  
SGOT  DC  HIV  
SGPT  Platelets  PT/INR  
SAP  Urine alb  MHE  Portal Doppler 
Tot prot  RBS  ECG  
S.alb  Bl.urea  Echo  
S.glob  S.creat    
 
Esophago gastroduodenoscopy: 
Presence of varices:                                                               Grading :            
Ascitic fluid analysis: 
TC                         DC                          Protein                       Albumin                 SAAG                Cytology 
Culture and sensitivity                 
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Master Data 
Name Age  Sex  
Duration 
Of Illness Etiology  
 UGI 
Bleed Admissions MELD CTP SAP 
Platelet 
Count  
Palani  45 Male 2 yrs Ethanol 1 16 13 b 247 72000 
Periyanayagam 60 Male 3 month Ethanol/HBV 0 2 17 b 144 66000 
Sampath  53 Male 16 years HBV 0 5     146 52000 
Madhavan 54 Male 1 year Ethanol 0 2 16 8b 343 123000 
Ramadoss 47 Male 6 months Ethanol 0 5 15 12c 192 42000 
Valli 34 Female 4 years  HBV 1 2     214 49000 
Sallaikannan 43 Male 6 months Ethanol/HBV 0 5     245 91000 
Murugan 40 Male 6  months Ethanol 1 2 18 10c 353 30000 
Krishnamoorthy 70 Male 2 years Ethanol 0 7 16 12c 46 65000 
Mannammal 60 Female 5 years Ethanol 1 4     231 80000 
Velmurugan 44 Male 1 year Ethanol 1 4 18 9b 428 41000 
Dekesnamoorthy 55 Male 2 years Ethanol 1 4     100 100000 
Ramanaathan 33 Male 4 months Ethanol 1 1 17 10c 305 41000 
Madhavamahendran 57 Male 7 years HBV 1 3     179 68000 
Arumugam 40 Male 5 months Ethanol 0 1     442   
Balakrishnan 40 Male 3 years Ethanol 2 1 17 9b 284 133000 
Ravi 49 Male 3 months Ethanol 0 1     311 180000 
Babu 40 Male 1 year Ethanol 0 3     415 41000 
Ramu 42 Male 1 year Cryptogenic 0 0     120 120000 
Pounnuammal 55 Female 3 months Cryptogenic 0 1     410 109000 
Suburamani 56 Male 
18 
months Ethanol 1 1 18 9b 261 164000 
Pasupathi 44 Male 
18 
months Ethanol 0 1     311 100000 
Rameja 48 Female 3 months NASH 0 3 8 9b 219 189000 
Kayatharu 49 Male 3 months Cryptogenic 0 0     320   
Vijayalakshmi 44 Female 1 month NASH 0 0     184 58000 
Dhanam 45 Female 5 years EHPVO/hcv 0 0     48 189000 
Amaravathi 40 Female 8 years NASH 0 5 18 7d 200 33000 
Venketashan 42 Male 8 months Ethanol 1 1 11 9b 228 45000 
Sathyaraj 64 Male 1 year Ethanol     7 6a 142 61000 
Vijayalakshmi 65 Female 6 years Cryptogenic 1 1     88 180000 
Karunakaran 45 Male 6 years Ethanol 1 4     187 88000 
Arunachalam 50 Male 5 years Ethanol 1 3     140 75000 
Kanniyappan 54 Male 3 months Ethanol 0 1 22 11c 384 181000 
Baskar 48 Male 6 months Ethanol 1 2     274   
Baskaran 38 Male 2 years Ethanol 1 2 17 10c 497 190000 
Durai 50 Male 2 months Ethanol 1 0 12 10c 752 82000 
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Ramesh 41 Male 6 months Ethanol 0 3 14 9c 531 62000 
Baskaran 57 Male 6 months Ethanol 0 2 23 10c 313 56000 
Gopinath 35 Male 1 year ethanol 0 6 22 11c 269 180000 
Devaraj  33 Male 2 years Ethanol 0 2     94 19200 
Muniyandi 52 Male 1 Month Ethanol 0 1 13 8b 298 208000 
Koteeswaran 49 Male 5 years Ethanol 0 5 28 13c 275 100000 
Devarajan 41 Male 5 months Ethanol 0 0 18 10c 125 93000 
Vijayakumari 58 Female 
18 
months NASH 0 2 23 8b 749 103000 
Hariharan 60 Male 4 years  Ethanol 2 3 16 10c 219 130000 
Sam 44 Male 4 years  Ethanol 0 1 24 11c 379 93000 
Kalavathy 50 Female 2 years HBV 0 2 9 5a 92 140000 
Dhayalan 47 Male 2 years Ethanol 0 1 18 9b 235 116000 
Ravi Kumar 44 44 Male 6 months Ethanol 0 2     438 204000 
Murugan  40 Male 1 year Ethanol 1 2 18 10c 285 30000 
Palani  45 Male 2 years Ethanol 0 2     287 21000 
Veera Ragavan 57 Male 1 year Cryptogenic 1 2 17 11c 493 62000 
Vimala 35 Female 3 months Cryptogenic 1 1 12 9b 154 43000 
Poongavanam 61 Male 3 months Ethanol 0 1 11 8b 366 180000 
Devasagayam 47 Male 2 months Cryptogenic 0 0     75 83000 
Palani  42 Male 3 years Ethanol 0 2 19 11c 147 157000 
Ravi Chandran 45 Male 6 years Ethanol 1 4     125 156000 
Manoharan 60 Male 3 years Ethanol 3 0     101   
Malathy 59 Female 2 years NASH 0 1 14 9b 229 310000 
Subburathinammal 40 Female 3 years Autoimmune 2 2 14 8b 231 56000 
Jayakumar 39 Male 6 months Ethanol/HBV 1 1 10 8b 211 160000 
Jaishankar 50 Male 6 months Ethanol 1 1 11 7b 227 111000 
Sasikumar 38 Male 8 months Ethanol/HBV 1 1 20 11c 303 44000 
Chellamuthu 60 Male 9 months Ethanol 0 1     140   
Ravi 54 Male 9 months Ethanol 0 0     129   
Sivakumar 35 Male 2 years Ethanol 1 5 26 13c 292 88000 
Bishma Rao 48 Male 
12 
months Ethanol 2 1 17 9b 431 250000 
Hameedha Begam 55 Female 3 years HCV 4 4 6 5a 154 80000 
Santhanam 51 Male 4 years  Ethanol 0 0     274 99000 
Ezhumalai  53 Male 3 years HBV 3 4 14 8b 158 66000 
Jeyakumar 45 Male 2 years  Ethanol 0 4 18 9c 185 88000 
Sudha 38 Female 3 months  Cryptogenic 0 0 12 8b 182 74000 
Chokkalingam 57 Male 6 years  Ethanol 0 0 11 9b 81 206000 
Devarajan 41 Male 6 months Ethanol 0 0 17 11 c 133 93000 
Govindharaj 58 Male 5 years Ethanol 2 3 17 11c 110 120000 
Rani  55 Female 3 years Ethanol 0 2 12 8b 105 150000 
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Govindharaj 38 Male 4 yeas Ethanol 1 3 11 8b 176 106000 
Ramachandran 45 Male 2 years Ethanol 0 2 13 9b 106 342000 
Lakshmi 56 Female 6 years NASH 3 2 12 7b 331 149000 
Anbarasu 38 Male 2 years Ethanol 0 3 18 10c 251 120000 
Uthirapthy 42 Male 2 years Ethanol 1 3 17 10c 187 260000 
Ravi 48 Male 3 years Ethanol 0 10 18 11c 223 260000 
 
Name 
Diabet
es 
Cirrh 
Cardi
o 
PV
T 
Beta 
Block
er 
Norflo
x SBP 
Refracto
ry 
Ascites 
HR
S 
H
E VOGD 
Palani  No     No no 2 12 2 2 Normal 
Periyanayagam No   no Yes no   0 0 0 2-3 Varices 
Sampath  No   yes  No no   0 0 0 1-2 Varices 
Madhavan No   no No yes 1 0 0 0 PHG 
Ramadoss Yes no no No yes 4 5 1 2 PHG 
Valli No no   No no   0 0 0 1-2 Varices 
Sallaikannan No     Yes yes 4 4 0 0 1-3 Varices, PHG 
Murugan No no no Yes no   0 0 0 1-2 Varices 
Krishnamoorthy No yes   Yes no 3 5 0 0 3 Varices 
Mannammal No no no No yes 1 0 0 1 Normal 
Velmurugan No     No no 3 0 1 2 2 Varices 
Dekesnamoorthy Yes     Yes no 1 0 0 0 2-3 Varices, PHG 
Ramanaathan No     Yes no   0 0 0 1 Varices, Gov2 
Madhavamahend
ran No     Yes no   0 0 0 1-3 Varices, PHG 
Arumugam No yes   No yes 1 0 0 0 PHG 
Balakrishnan No     Yes no   0 0 0 2-3 Varices, PHG 
Ravi No no   No no   0 0 0 Normal 
Babu No     Yes yes 1 0 0 1 1-2 Varices 
Ramu No no no No no   0 0 0 1-2 Varices 
Pounnuammal Yes   no No no 1 0 0 0 Normal 
Suburamani No yes   No no 1 0 0 0 1-2 Varices 
Pasupathi No     Yes no   0 0 0 2-3 Varices, PHG 
Rameja Yes     No yes 1 0 0 2 1-2 Varices, PHG 
Kayatharu No     Yes no   0 0 0 1-2 Varices, PHG 
Vijayalakshmi Yes no no No no   0 0 0 2 Varices 
Dhanam No   no Yes no   0 0 0 1-3 Varices, PHG 
Amaravathi Yes     Yes no 3 2 0 3 2-3 Varices, PHG 
Venketashan No   no No no   0 0 0 3 Varices 
Sathyaraj Yes no no No no   0 0 0   
Vijayalakshmi No     Yes no   0 0 0 3 Varices 
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Karunakaran No     Yes no 2 0 0 0 1-3 Varices, PHG 
Arunachalam Yes     Yes yes   0 0 1 2-3 Varices 
Kanniyappan No yes no No yes   0 0 0 1 Varices 
Baskar Yes     Yes no   0 0 0 2-3 Varices, PHG 
Baskaran Yes no   Yes yes   0 1 0 2 Varcies, Gov1, PHG 
Durai No no no No no   0 0 0 Normal 
Ramesh No     No yes 2 0 0 1 1 Varices 
Baskaran Yes no no Yes no 1 1 0 1 2 varcies, PHG 
Gopinath No no no No yes 4 2 1 2 1-2 Varices 
Devaraj  No   no Yes no   0 0 0 2-3 Varices 
Muniyandi No     No no   0 0 0 1 Varices 
Koteeswaran No     Yes yes 3 3 0 1 1-3 Varices, PHG 
Devarajan No     No no   0 0 0 PHG 
Vijayakumari Yes   no Yes yes   0 0 0 PHG 
Hariharan No     Yes yes   0 0 1 1 Varices, IGV-1 , GOV-1 
Sam No     No no   0 0 0 PHG 
Kalavathy No     Yes no   0 0 0 1-3 Varices 
Dhayalan No yes no Yes yes   0 1 0 1-2 Varices 
Ravi Kumar 44 No   no No yes 1 1 0 0 1 Varices, PHG 
Murugan  No no no Yes yes   0 0 0 1-2 Varices 
Palani  No no   No no   0 0 0 Normal 
Veera Ragavan No yes no Yes no   0 0 0 1-3 Varices, PHG 
Vimala No   no Yes no   0 0 0 1-3 Varices, PHG 
Poongavanam No   no Yes yes   0 0 0 2-3 Varices, PHG 
Devasagayam Yes no   Yes yes   0 0 0 1-2 Varices 
Palani  No no no No yes   0 0 1 PHG 
Ravi Chandran No no   No no 1 0 1 3 Gastritis 
Manoharan No no   Yes yes 1 0 0 1 1-2 Varices, PHG 
Malathy Yes no no No no   0 0 0 GAVE 
Subburathinamm
al No no   Yes no   0 0 0 2-3 Varices, PHG 
Jayakumar No no   Yes yes 1 0 0 0 
1 Varices, duodenal and 
prepyloric ulcer 
Jaishankar No yes no No no 1 0 0 0 PHG 
Sasikumar No     No yes   0 0   1 Varices 
Chellamuthu No   yes  No no   0 0 0 Duodenitis 
Ravi No     Yes yes   0 0 0 1-2 Varices 
Sivakumar No yes no Yes no 2 5 0 0 1 Varices, PHG 
Bishma Rao No no no Yes no   0 0 0 2-3 Varices, PHG 
Hameedha 
Begam No no no Yes no   0 0 0 3 Varices, PHG 
Santhanam No no   No yes   0 0 0 1 Varices 
Ezhumalai  Yes no no Yes no   0 0 0 3 Varices, PHG 
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Jeyakumar Yes no no Yes yes 1 0 0 0 1-2 Varices 
Sudha No no no Yes no   0 0 0 2-3 Varices 
Chokkalingam No no no No no   0 0 0 1-2 Varices 
Devarajan No no no No yes   0 0 0 PHG 
Govindharaj No yes no Yes yes 2 0 0 0 3 Varices, PHG 
Rani  No yes no Yes no   0 0 0 3 Varices, PHG 
Govindharaj No no no Yes yes 1 0 0 0 3 Varices 
Ramachandran No no no No yes 1 0 0 1 1 Varices 
Lakshmi Yes   no Yes yes 1 0 0 0 2-3 Varices 
Anbarasu No no no No yes 1 0 0 0   
Uthirapthy No no no No no 1 0 0 0   
Ravi No no no No yes 7 5 2 2 PHG 
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